KBIO In Detox Mode, CTIC Abuzz, MYL Does Damage Control, D-Day For RIGL

Rigel Pharmaceuticals Inc. (RIGL) will be announcing the results of the first of two phase III studies of Fostamatinib for patients with immune thrombocytopenia at 7:00 a.m. Eastern Time on Tuesday, August 30, 2016.

from RTT - Biotech http://ift.tt/2caMg4a
via IFTTT